Lilly's retatrutide delivers 30% weight loss in Phase 3 TRIUMPH-1 trial

All three dose levels, 4 mg, 9 mg and 12 mg, successfully met the primary and key secondary endpoints in 80 weeks

FDA expands Enhertu use in early HER2-positive breast cancer

AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease

OrganaBio expands cell therapy manufacturing footprint with acquisition of Excellos Assets

The deal also establishes a new subsidiary, Excellos Labs, which will oversee continued operations in San Diego

FDA grants accelerated approval to BEQALZI for relapsed mantle cell lymphoma

Teva study exposes major diagnosis gap in Tardive Dyskinesia

According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD

Lupin launches Atharv ability neuro-rehabilitation centre in Delhi

New Delhi facility expands Lupin’s specialized neuro-rehabilitation network after Mumbai and Hyderabad launches

Mankind launches ‘Act at 30’ campaign to push early heart health screening

Nationwide preventive health initiative aims to make cardiovascular screening at age 30 a standard healthcare milestone

Experts calls for urgent preventive action as hypertension cases rise

Union Minister Prataprao Jadhav terms hypertension a “silent killer”; experts push for early screening, lifestyle correction and wellness-focused healthcare

Dr. Reddy’s launches generic semaglutide in Canada

Dr. Reddy’s is the first company to receive Health Canada approval for generic Semaglutide Injection in Canada

Alembic Pharma receives USFDA tentative approval for Darolutamide tablets

Darolutamide Tablets, 300 mg, had an estimated market size of US$ 3,155 million in the United States